Potent and novel 11β-HSD1 inhibitors identified from shape and docking based virtual screening.

[1]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[2]  R. Rosmond.  The glucocorticoid receptor gene and its association to metabolic syndrome. , 2002, Obesity research.

[3]  L. Abrahmsén,et al.  Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. , 2002, Journal of medicinal chemistry.

[4]  R. Kahn,et al.  The metabolic syndrome: time for a critical appraisal , 2005, Diabetologia.

[5]  J. Tuomilehto,et al.  The metabolic syndrome and cardiovascular risk. , 2005, Current diabetes reviews.

[6]  G. Klebe.  Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[7]  E. Bonora,et al.  Metabolic syndrome and cardiovascular disease , 2007, Annals of clinical biochemistry.

[8]  Didier Rognan,et al.  Assessing the Scaffold Diversity of Screening Libraries , 2006, J. Chem. Inf. Model..

[9]  P. Stewart,et al.  Modulation of glucocorticoid action and the treatment of type-2 diabetes. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[10]  J. Seckl,et al.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. , 2007, Drug discovery today.

[11]  G. Matfin.  Challenges in developing drugs for the metabolic syndrome , 2008, Current diabetes reports.

[12]  Minghan Wang,et al.  Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes , 2008 .

[13]  E. Saiah.  The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors. , 2008, Current medicinal chemistry.

[14]  K. Svenson,et al.  Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. , 2009, Journal of medicinal chemistry.

[15]  Maria A Miteva,et al.  Structure-based virtual ligand screening: recent success stories. , 2009, Combinatorial chemistry & high throughput screening.

[16]  Bing Xiong,et al.  ScafBank: a public comprehensive Scaffold database to support molecular hopping , 2009, Acta Pharmacologica Sinica.

[17]  Jianhua Shen,et al.  4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice. , 2009, Bioorganic & medicinal chemistry letters.

[18]  Jiandong Zhang,et al.  Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221). , 2010, Journal of medicinal chemistry.

[19]  Maria João Ramos,et al.  Virtual screening in drug design and development. , 2010, Combinatorial chemistry & high throughput screening.